Race Oncology hits 12-month high with new multiple myeloma findings

Proactive - Interviews for investors

Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett speaks to Proactive about the potential clinical utility of its lead asset, bisantrene. The biotech this week reached a new 12-month high following strong preclinical findings on the efficacy of bisantrene in treating multiple myeloma. Shares increased by 7.95% to A$2.04, with the company's market capitalisation around A$339.25 million. Multiple myeloma, a dangerous blood cancer more common in men over 60, accounts for 10% of blood cancers with a five-year survival rate of 55.6%. Carfilzomib, a drug used for relapsed or refractory multiple myeloma, carries known cardiotoxicity risks, particularly in patients with pre-existing heart conditions. Preclinical studies performed by Labcorp USA indicated that bisantrene, both alone and in combination with carfilzomib, slows disease progression and enhances carfilzomib's efficacy. Bisantrene killed human multiple myeloma cells at clinically relevant concentrations in both cell cultures and mice, and in combination with carfilzomib, showed enhanced activity, suggesting a potentially safer treatment. In 2021, Race discovered that bisantrene could protect human heart muscle cells from carfilzomib's toxicity. Mouse model studies showed that bisantrene significantly slowed multiple myeloma progression, while carfilzomib alone, at its maximum tolerated dosage, showed no single-agent activity. The combination of bisantrene and carfilzomib proved more effective than bisantrene alone, indicating a synergistic effect. Race plans further preclinical studies to investigate the cellular mechanisms of the delayed progression of multiple myeloma and to confirm bisantrene's cardioprotective properties. The company also intends to explore clinical studies to evaluate the combination treatment for multiple myeloma patients. #ProactiveInvestors #RaceOncology #ASX #RAC #MultipleMyeloma, #Bisantrene, #Carfilzomib, #CancerResearch, #PreclinicalStudies, #BloodCancer, #CancerTreatment #Oncology #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews